Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2001, p. 96-104, Vol. 45, No. 1
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.1.96-104.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Effects of Cytokines and Fluconazole on the
Activity of Human Monocytes against Candida
albicans
A. L.
Baltch,*
R. P.
Smith,
M. A.
Franke,
W. J.
Ritz,
P.
B.
Michelsen, and
L. H.
Bopp
Stratton Veterans Affairs Medical Center and
Albany Medical College, Albany, New York
Received 7 April 2000/Returned for modification 9 June
2000/Accepted 13 October 2000
 |
ABSTRACT |
This study evaluates the effects of cytokines, used singly and in
combination, on the microbicidal activity of human monocyte-derived macrophages (MDM) against intracellular Candida albicans in
the presence and absence of fluconazole. In the absence of fluconazole, the addition of tumor necrosis factor alpha (TNF-
), interleukin-1
(IL-1
), gamma interferon (IFN-
), or IL-4 had no effect on the growth of C. albicans. In contrast, the addition of
granulocyte-macrophage colony-stimulating factor (GM-CSF) resulted in
decreased growth (P < 0.05), while the addition of
IL-10 resulted in increased growth (P < 0.01). In the
presence of fluconazole, only the addition of IFN-
resulted in an
increase in the growth of C. albicans. In the presence or
absence of fluconazole, all cytokine combinations except IFN-
plus
GM-CSF caused significant decreases in growth (P < 0.01). IL-10 and IL-4 did not influence the activity of TNF-
or
IL-1
. In the absence or presence of C. albicans the
addition of fluconazole, all of the cytokines studied, and combinations of fluconazole and selected cytokines caused increases in nitric oxide
(NO) production (P < 0.01). Similar observations were
made for superoxide (O2
) only in the presence
of C. albicans. The greatest concentrations of NO and
O2
were produced when C. albicans
alone was present in the assays. Our results demonstrate that in the
presence of low concentrations of fluconazole (0.1 times the MIC),
selected cytokines and their combinations significantly increase the
microbicidal activity of MDM against intracellular C. albicans.
 |
INTRODUCTION |
Invasive fungal infections,
including disseminated candidiasis, are usually associated with high
morbidity and mortality in debilitated and immunocompromised hosts,
even when they are receiving appropriate antifungal agents (2, 5,
15, 22, 41). Phagocytic cells, using both oxidative and
nonoxidative mechanisms, provide the primary host defense against
microbial pathogens, including fungi (2, 8, 12, 13, 30, 32,
59). In addition, cell-mediated immunity and mechanical barriers
protect the host. However, chemotherapeutic agents, corticosteroids,
and radiation, which are often used in the treatment of malignant disease and AIDS, and for transplantation patients, disrupt these defense mechanisms. If patients are to survive infections associated with neutropenia and other compromises in host defense due to the use
of these therapies, it is important to reverse or at least lessen
immunosuppression in these patients. By doing so, serious infections
such as disseminated candidiasis, which recent reports indicate has a
mortality rate of 30 to 95%, may be avoided (5, 7, 22,
61).
Monocytes are an important component of cellular defense mechanisms in
humans (8). When stimulated by microbes, monocyte eicosanoid metabolism is altered, arachidonic acid is produced and
released, and there is an increase in the production of cytokines, including tumor necrosis factor alpha (TNF-
), interleukin-1
(IL-1
), IL-6, IL-8, granulocyte-macrophage colony-stimulating factor
(GM-CSF), and interferons (8, 9, 11, 27). As a result,
chemotaxis and phagocytosis are enhanced (8). The upregulated influx of activated inflammatory cells is an important mechanism by which the host can eliminate invading organisms. During
the past decade there has been general agreement that GM-CSF and gamma
interferon (IFN-
) enhance the phagocytic function and increase the
killing of Candida albicans (43, 48, 49, 52, 63). In addition, GM-CSF increases intracellular oxidative
metabolism, as demonstrated by an increase in superoxide
(O2
) production (8). A
monoclonal antibody against GM-CSF abolishes this effect. Thus, unless
monocytes are activated by cytokines such as GM-CSF, their
effectiveness in host defense is limited (8, 9). Because
GM-CSF and IFN-
have been shown to enhance phagocytic function, they
are frequently considered for use in patients who are undergoing
treatment for malignant disease, who are receiving bone marrow
transplants, or who have AIDS (3, 11, 24, 31, 34-37, 40,
58). In addition, cytokines such as IL-1
, IFN-
, and
TNF-
can stimulate the production of GM-CSF (34).
Finally, administration of white blood cells from donors given GM-CSF
has been associated with increased survival of neutropenic patients
undergoing cancer chemotherapy (1, 14, 36, 37). Although
no clearly established recommendations have been published, the use of
cytokines as therapeutic adjuvants in the prevention and/or treatment
of invasive fungal infections has been advocated (1, 7, 14,
35-37).
The purpose of this study was to define the intracellular interaction
between cytokines and subinhibitory concentrations of an antifungal
agent, fluconazole, against C. albicans, and to determine
which mechanisms are likely to be responsible for the observed
candidacidal activity of human monocytes. We studied the anticandidal
effects of adding the cytokines TNF-
, IL-1
, IL-4, IL-10, IFN-
,
and GM-CSF, singly and in combination, to assays with human
monocyte-derived macrophages (MDM) in the presence and absence of
subinhibitory concentrations of fluconazole. In addition, nitric oxide
(NO) and O2
determinations were performed in
order to define the oxidative capacity of the activated monocytes.
 |
MATERIALS AND METHODS |
Microorganism.
C. albicans strain T=6, referred
to below simply as C. albicans, was originally isolated from
the blood of a candidemic patient and was provided by the Wadsworth
Laboratories, New York State Department of Health, Albany, N.Y.
C. albicans was grown on Sabouraud dextrose agar for 48 h. For opsonization, several colonies were suspended in RPMI 1640 medium (Sigma Chemical Co., St. Louis, Mo.) containing 10% fresh
pooled normal human serum and were incubated for 30 min at 37°C. The
opsonized cells were then centrifuged and resuspended at a
concentration of 2 × 104 CFU/ml in RPMI 1640 medium
containing 10% fetal calf serum (FCS).
Antimicrobial agent.
Fluconazole was provided by Pfizer
Laboratories, Groton, Conn. Antibiotic solutions were made fresh for
each experiment in accordance with the supplier's instructions, filter
sterilized, and used immediately. The fluconazole MIC for C. albicans, determined according to NCCLS method M27-T, was 1 µg/ml (33).
Preparation of monocytes.
MDM were prepared from the
heparinized blood of healthy human donors who had signed the
informed-consent form approved by the Institutional Review Board of the
Albany Medical College and Stratton Veterans Affairs (VA) Medical
Center, Albany, N.Y. Mononuclear cells were separated from whole blood
by using Histopaque 1077 (Sigma). The resulting mononuclear cell
preparation was
98% pure. The separated cells were resuspended at a
concentration of 2 × 106 cells/ml in RPMI 1640 medium
containing 10% FCS, 100 U of penicillin G/ml, and 100 µg of
streptomycin/ml. Cell viability, determined by using the trypan blue
exclusion test, was
98%.
Cytokines.
All cytokines were obtained from R & D Systems,
Inc., Minneapolis, Minn. TNF-
, GM-CSF, and IL-10 were used at a
concentration of 100 U/ml. IL-1
, IFN-
, and IL-4 were used at a
concentration of 1,000 U/ml.
Study design.
Human mononuclear cells (2 × 106) were delivered to the wells of 24-well plates
(Corning/Costar Corp., Cambridge, Mass.) in a 1-ml volume and allowed
to adhere for 72 h. Monocytes adhered to the wells in a contiguous
layer. Medium and nonadherent cells, including lymphocytes, were
aspirated from the wells. The adherent monocyte layer was gently washed
once with RPMI 1640. TNF-
, IL-1
, IFN-
, and GM-CSF were added
to duplicate wells singly or in combination, and the monolayers were
incubated for 24 h in 5% CO2 at 37°C. In
experiments where IL-4 and IL-10 were used, IL-4 and IL-10 were added
to cells that had been pretreated with TNF-
. These cells were then
incubated for an additional 24 h. Opsonized C. albicans
(2 × 104 cells in a volume of 1 ml) suspended in RPMI
1640 plus 10% FCS was then added to the wells. One hour was allotted
to allow phagocytosis to occur. Nonphagocytosed blastoconidia were
removed by aspiration, and the cell layer was washed once with RPMI
1640. Cytokines were readministered to the monolayer, and 0.1 µg of
fluconazole (0.1 times the MIC) was then added in a 1-ml volume to each
well. Following incubation of the plates at 37°C in an atmosphere
containing 5% CO2 for 0, 24, and 48 h, the
supernatants were removed, the monocytes were lysed with distilled
water, and the lysates were quantitatively plated in duplicate on
Sabouraud dextrose agar. The plates were incubated for 24 h at
37°C, and the numbers of surviving organisms were determined. Control
wells contained monolayers of monocytes and either C. albicans, fluconazole, C. albicans plus fluconazole, or
appropriate cytokines singly or in combination. Each assay was repeated
three to six times.
NO and O2
assays.
NO
concentrations were determined using a nitrate/nitrite colorimetric
assay kit (Cayman Chemical, Ann Arbor, Mich.). This assay is based on
the enzymatic conversion of nitrate to nitrite by nitrate reductase.
Nitrite is detected by the production of a colored product using the
Greiss reaction. The concentration is then determined
spectrophotometrically. O2
concentrations
were determined using the method of Pick and Mizel (42).
In this procedure the detection of O2
is
based on the reduction of ferricytochrome c and measurement of the increase in absorbance at 550 nm. Each assay was repeated two to
eight times.
Statistical methods.
For time-kill curves (see Fig. 1 and
2), changes in the numbers of CFU per milliliter from 0 to 24 h,
as well as from 0 to 48 h and from 24 to 48 h, were compared
among experimental variables. The analysis of variance methodology
(53) was applied to the yeast counts following conversion
to log10 units. For NO and O2
concentrations (see Table 1 and Fig. 3 to 5), analyses were done at 24 and 48 h using the analysis of variance (53).
Contrasts were tested intra-assay. In addition, in Table 1, interassay comparisons were made between live or heat-killed C. albicans and controls. Null hypotheses were specified a priori.
The level of significance was 0.05.
 |
RESULTS |
Figure 1 shows the effects of
TNF-
, IL-1
, IFN-
, GM-CSF, IL-4, and IL-10, used singly, in the
presence or in the absence of fluconazole, in MDM assays. The numbers
of surviving yeasts in MDM treated with TNF-
, IL-1
, IFN-
, or
IL-4 alone were not significantly different from those in controls at
either 24 or 48 h (Fig. 1A, B, C, and E). In contrast, addition of
GM-CSF alone (Fig. 1D) resulted in a significant decrease in yeast
survival at 24 h (P < 0.05), while addition of
IL-10 resulted in an increase in yeast survival (Fig. 1F) (P < 0.01). In the presence of fluconazole, addition of IFN-
resulted in an increase in the number of surviving yeasts at 24 h
(Fig. 1C) (P < 0.01), and addition of GM-CSF, IL-4, or
IL-10 (Fig. 1D through F) caused a decrease in the number of surviving
yeasts at 48 h (P < 0.01). Fluconazole had no
effect in assays containing TNF-
or IL-1 (Fig. 1A and B). In the
presence of fluconazole, addition of each of the six cytokines
caused a reduction in the growth of the yeast from 24 to 48 h
(P < 0.05).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Time-kill curves demonstrating in vitro activity of
fluconazole (at 0.1 times the MIC) against intracellular C. albicans, with and without cytokines. (A) TNF- (100 U/ml); (B)
IL-1 (1,000 U/ml); (C) IFN- (1,000 U/ml); (D) GM-CSF (100 U/ml);
(E) IL-4 (1,000 U/ml); (F) IL-10 (100 U/ml). Solid circles, control;
open circles, fluconazole alone; solid inverted triangles, cytokine
alone; open inverted triangles, fluconazole plus cytokine.
|
|
The results in Fig. 2 demonstrate the
effects of combinations of IFN-
and GM-CSF, TNF-
and IL-10,
IL-1
and IL-10, IL-4 and IL-10, and TNF-
, IL-4, and IL-10, in the
presence and absence of fluconazole, after 24 and 48 h of
incubation. With or without fluconazole, all combinations of cytokines
except IFN-
plus GM-CSF caused a significant decrease in the growth
of C. albicans from 0 to 48 h and from 24 to 48 h.
On average, there was significantly less growth than in the
controls (P < 0.01). In contrast, no significant differences were observed between the growth of C. albicans
in control monolayers and that in monolayers treated with IFN-
plus GM-CSF, with or without fluconazole (Fig. 2A). The
anti-inflammatory cytokine IL-10 did not negate the activity of
proinflammatory cytokines in our assay system, and there was no
potentiation of anti-inflammatory cytokine activity when IL-4 and IL-10
were used together (Fig. 2D).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Time-kill curves demonstrating in vitro activity
of fluconazole (Flu; at 0.1 times the MIC) against intracellular
C. albicans, with and without combinations of
cytokines. (A) IFN- plus GM-CSF; (B) TNF- and IL-10; (C) IL-1
and IL-10; (D) IL-4 and IL-10; (E) TNF- , IL-4, and IL-10.
|
|
Table 1 shows the NO and
O2
concentrations at 0, 24, and 48 h in
wells containing MDM in the absence and presence of live or heat-killed
C. albicans, with and without fluconazole. At 0 h the
concentrations of NO and O2
in wells
containing MDM but not C. albicans or fluconazole were very
low. Under these conditions, the highest concentrations were reached at
24 h. Treatment of MDM with fluconazole caused an increase in the
NO concentration but did not affect the concentration of O2
. In the presence of either live or
heat-killed C. albicans and with no fluconazole, NO and
O2
concentrations increased dramatically at
24 h (P < 0.01). The greatest increases occurred
in the presence of heat-killed C. albicans. In assays
containing MDM and either live or heat-killed C. albicans,
the NO concentrations at 24 h were 50% lower in the presence of
fluconazole than in its absence (P < 0.01). However, the O2
concentration was lower (P < 0.01) in the presence of fluconazole only in the assay
containing live C. albicans. At 48 h contrasts remained
essentially the same, although in the presence of fluconazole, NO
concentrations did not increase as markedly with the addition of
C. albicans. O2
concentrations at
48 h were lower (P < 0.01) when fluconazole and
heat-killed C. albicans were added to MDM.
Figures 3 to 5 show the concentrations of NO and
O2
in MDM assays at 24 and 48 h in the
presence of cytokines (singly), fluconazole, or combinations of
cytokines and fluconazole, with and without C. albicans. The
average concentrations for controls are also given. In the absence of
C. albicans, TNF-
, IFN-
, GM-CSF, and IL-10 each caused
a significant increase in the concentration of NO at both 24 and
48 h (Fig. 3A) (P < 0.01). Fluconazole alone also caused a significant increase at
both 24 and 48 h (Fig. 4A). Significant increases in the NO concentration also occurred at 24 and
48 h when fluconazole was combined with either TNF-
or IL-10
(Fig. 5A) (P < 0.01).
Addition of fluconazole and GM-CSF resulted in an increase in the NO
concentration only at 48 h (Fig. 5A) (P < 0.01).
With the exception of fluconazole plus IL-10 at 48 h, the
concentrations of NO were lower (P < 0.01) in the
presence of fluconazole and individual cytokines (Fig. 5A) than they
were in the presence of the cytokines alone (Fig. 3A). In contrast to
the changes in NO concentrations, no significant changes were observed
in O2
concentrations in the absence of
C. albicans (Fig. 3B, 4B, and 5B).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Concentrations of nitric oxide (A and C) and superoxide
(B and D) produced by MDM pretreated with TNF- , GM-CSF, IL-10, or
IFN- and either not exposed (A and B) or exposed (C and D) to
C. albicans. Asterisks indicate significant differences from
controls: * P < 0.05; **, P < 0.01.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Concentrations of nitric oxide (A and C) and superoxide
(B and D) produced by MDM pretreated with fluconazole (Flu) and either
not exposed (A and B) or exposed (C and D) to C. albicans.
*, P < 0.05; **, P < 0.01.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Concentrations of nitric oxide (A and C) and superoxide
(B and D) produced by MDM pretreated with combinations of fluconazole
and TNF- , GM-CSF, IL-10, or IFN- , and either not exposed (A and
B) or exposed (C and D) to C. albicans. *, P < 0.05; **, P < 0.01.
|
|
In MDM assays containing TNF-
, IFN-
, GM-CSF, IL-10, fluconazole
alone, or combinations of the cytokines with fluconazole in the
presence of C. albicans, NO concentrations at 24 h were significantly lower (P < 0.01) than those in controls
containing only MDM and C. albicans (Fig. 3C, 4C, and 5C).
However, except when MDM were treated with GM-CSF plus fluconazole,
these same NO concentrations were higher (P < 0.01)
than those in control assays containing MDM but not C. albicans (Fig. 3A, 4A, and 5A). At 48 h, fluconazole alone
(Fig. 4C) (P < 0.01) and fluconazole plus IL-10 (Fig.
5C) (P < 0.05) caused the NO concentration to decrease, while increases in NO concentrations were observed with the
addition of IL-10 alone (Fig. 3C) (P < 0.01) and
fluconazole plus GM-CSF (Fig. 5C) (P < 0.05). In
contrast to the changes in NO concentrations,
O2
concentrations did not change
significantly in the presence of cytokines and C. albicans.
However, significant decreases in O2
concentrations were observed at both 24 and 48 h in assays
containing fluconazole and C. albicans (Fig. 4D)
(P < 0.01) and in assays containing IFN-
or
IL-10, fluconazole, and C. albicans (Fig. 5D) (P < 0.01). In assays containing TNF-
or GM-CSF plus fluconazole and C. albicans, the O2
concentrations were lower than those of the controls, although only the differences at 48 h were significant (Fig. 5D)
(P < 0.01). In the presence of C. albicans,
the addition of individual cytokines or fluconazole combined with
either TNF-
or GM-CSF caused the O2
concentration to increase at 24 h compared to that in controls containing MDM but not C. albicans (P < 0.01).
Thus, in MDM assays lacking C. albicans but containing
cytokines (Fig. 3A), fluconazole (Fig. 4A), or cytokines plus
fluconazole (Fig. 5A), NO concentrations were higher than those in
controls containing MDM alone. However, in assays containing C. albicans and cytokines, fluconazole, or cytokines plus
fluconazole, NO concentrations were significantly lower than those in
controls containing only MDM and C. albicans.
O2
concentrations were unaffected by
cytokines or fluconazole in the absence of C. albicans (Fig.
3B, 4B, and 5B). However, when fluconazole alone (Fig. 4D) or
fluconazole and cytokines (Fig. 5D) were present along with C. albicans in MDM assays, O2
concentrations were significantly lower than those in controls containing only MDM and C. albicans.
 |
DISCUSSION |
Human monocytes and macrophages are important components of host
defense against pathogens (7, 8, 18, 61). However, they
require activation in order to achieve full antimicrobial activity
(8). This activation occurs as a result of exposure to
mannan, an important component of the C. albicans cell wall, as well as following exposure to some cytokines (8, 9, 26, 55,
57, 62, 63). The microbicidal activity of monocytes is related
to the oxygen burst mechanisms in the cell and may be strain and
species dependent (8, 10, 12, 17, 19, 23, 29, 30, 59, 61).
Fluconazole is a fungistatic triazole drug that inhibits the formation
of C. albicans hyphae and is concentrated in human
phagocytes (1, 2, 51, 56). Fluconazole interferes with
14-
demethylation of sterols, resulting in the accumulation of
14-
-methylated sterols in the cell membrane. C. albicans
cells with 14-
-demethylated sterols are especially vulnerable to the
oxygen-dependent microbicidal activity of phagocytes in which the
initial oxygen product is O2
(51). Furthermore, the inability of the
14-
-demethylation-deficient cells to form hyphae may allow the
fungus to be more easily ingested by phagocytes (51).
It has been clearly demonstrated in a murine model of disseminated
candidiasis that certain cytokines produced by monocytes, for example
TNF-
, increase survival (4, 6, 27, 28). Furthermore,
the use of GM-CSF in the treatment of neutropenic cancer patients with
systemic, invasive fungal infections has been shown to improve patient
survival (14, 16, 18, 21, 34-37, 40, 43, 44, 48, 49, 61).
Our study was undertaken in order to define the activities of six
cytokines used singly and in combination, in the presence and absence
of fluconazole, in a human MDM assay against a fluconazole-sensitive
C. albicans strain. In addition to evaluation of the
importance of cytokines in candidacidal activity, the mechanism of this
activity was evaluated by determining the O2
and NO concentrations in cells following exposure to cytokines and
fluconazole in the presence and absence of C. albicans.
Our results demonstrate that in the presence or absence of fluconazole,
TNF-
and IL-1
had no effect on the microbicidal activity of the
monocytes. In contrast, while IFN-
had no effect on the
intracellular killing of the yeast in the absence of fluconazole, in
the presence of fluconazole IFN-
stimulated intracellular killing at
24 h (P < 0.01). GM-CSF increased microbicidal
activity at 24 h in the absence of fluconazole (P < 0.05). In addition, GM-CSF increased the candidacidal activity of
MDM in the presence of fluconazole at 48 h (P < 0.01). Similar observations with GM-CSF at 24 h have been
described previously, although the assay procedures described differed
from ours (20, 31). Of interest was our observation that
without fluconazole, microbicidal activity was lower at 24 h in
the presence of IL-10 than in the controls (P < 0.01)
but that at 48 h the presence of IL-10 was associated with
increased microbicidal action (P < 0.01) in both the
presence and the absence of fluconazole. Suppression of the
microbicidal effect of macrophages by IL-4 and IL-10 in the absence of
fluconazole has been described previously (25, 38, 46, 47, 54,
60, 61). We observed a 13-fold increase in NO concentration in
the presence of MDM exposed to live C. albicans. In
addition, we demonstrated that the NO concentrations in assays that
included cytokines and/or fluconazole along with C. albicans
were low compared to the NO concentrations in assays containing only
MDM and C. albicans. Combinations of GM-CSF plus IFN-
had
no effect on microbicidal activity, regardless of the presence or
absence of fluconazole. In contrast, combinations of TNF-
plus
IL-10, IL-1
plus IL-10, IL-4 plus IL-10, and TNF-
plus IL-4 and
IL-10 were associated with significantly increased microbicidal
activity at 48 h and from 24 to 48 h (P < 0.01) in the absence or presence of fluconazole. In contrast to
TNF-
, IL-1
, and IFN-
, GM-CSF, IL-4, and IL-10 increased the
microbicidal activity of MDM in the presence of fluconazole. Since this
effect was significantly greater when fluconazole was present in the
assay, our data support the use of selected cytokines when fluconazole
is used for the therapy of disseminated candidiasis.
In this study we assessed the production of NO and
O2
by MDM activated by cytokines alone,
fluconazole alone, C. albicans alone, and combinations of
these. The roles of NO and O2
during
infection are complex. In contrast to the observations of Schneeman et
al. (50), we detected NO production by MDM that had been
stimulated by cytokines, fluconazole, and combinations of cytokines and
fluconazole (Table 1; Fig. 3 to 5). The regulation of NO production by
cytokines and the effect it has on the microbicidal activity of
monocytes remain incompletely understood (12, 30). It is
known, however, that NO production is enhanced in macrophages stimulated with TNF-
, IFN-
, IL-1, and IL-2 (10, 23, 29, 32). We demonstrated increased NO production by MDM stimulated with TNF-
and IFN-
, as well as by MDM stimulated with GM-CSF. Although previous observations indicate that IL-4 and IL-10 do not
induce NO synthetase production (29, 30), IL-10 stimulated NO production by MDM in our assays. Macrophages exposed to pathogens causing mycobacterial infections, malaria, viral hepatitis, and AIDS
show enhanced NO production (12). NO and its derivatives are important as antimicrobial effectors, with activity against parasitic, fungal, bacterial, and viral infection (12,
30). Evidence for the elaboration by C. albicans of a
soluble factor inhibiting NO production has recently been described
(10). Similarly to NO, O2
production by MDM was greatly enhanced by exposure to live C. albicans. Although cytokines alone did not affect
O2
production by MDM exposed to live C. albicans (Fig. 3D), the presence of fluconazole or fluconazole
plus cytokines resulted in a reduction in O2
concentrations in MDM assays containing C. albicans (Fig. 4D and 5D).
In our assays there was no clear correlation between NO and
O2
production and intracellular killing of
C. albicans by human monocytes. The fact that maximum
production of NO and O2
occurred when
monocytes were exposed to C. albicans alone and that NO and
O2
production were suppressed in monocytes
exposed to C. albicans in the presence of cytokines and/or
fluconazole emphasizes the complexity of the interaction of C. albicans with host macrophages.
The results described in our study clearly indicate that the
microbicidal activity of human monocytes is closely associated with the
activities of selected cytokines. Furthermore, subinhibitory concentrations of fluconazole increase these cytokine-specific effects
against fluconazole-sensitive intracellular C. albicans. These results support the use of selected cytokines as adjunctive therapy in disseminated candidiasis. However, the mechanism by which
cytokines and fluconazole enhance intracellular killing of C. albicans by human monocytes warrants further investigation.
 |
ACKNOWLEDGMENTS |
This work was supported by Pfizer Laboratories and in part by the
Veterans Affairs Research Service.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Infectious
Disease Research, Stratton VA Medical Center, Albany, NY 12208. Phone:
(518) 462-3311, ext. 3080. Fax: (518) 462-3350. E-mail:
BALTCH.ALDONA_{at}ALBANY.VA.GOV.
 |
REFERENCES |
| 1.
|
Anaissie, E. J.
1998.
Immunodulation in the treatment of invasive fungal infections: present and future directions.
Clin. Infect. Dis.
26:1264-1265[Medline].
|
| 2.
|
Andriole, V. T.
1999.
Current and future antifungal therapy: new targets for antifungal agents.
J. Antimicrob. Chemother.
44:151-162[Abstract/Free Full Text].
|
| 3.
|
Atkinson, K.,
J. C. Biggs,
K. Downs,
C. Juttner,
K. Bradstock,
R. M. Lowenthal,
B. Dale, and J. Szer.
1991.
GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes.
Aust. NZ J. Med.
21:686-692[Medline].
|
| 4.
|
Aybay, C., and T. Imir.
1996.
Tumor necrosis factor (TNF) induction from monocyte/macrophages by Candida species.
Immunobiology
196:363-374[Medline].
|
| 5.
|
Beck-Sague, C. M., and W. Jarvis.
1993.
National nosocomial infections surveillance system. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990.
J. Infect. Dis.
167:1247-1251[Medline].
|
| 6.
|
Blasi, E.,
L. Pitzurra,
M. Puliti,
R. Mazzolla,
R. Barluzzi,
S. Saleppico, and F. Bistoni.
1994.
Different events involved in the induction of macrophage tumor necrosis factor by Candida albicans and lipopolysaccharide.
Cell. Immunol.
157:501-509[CrossRef][Medline].
|
| 7.
|
Bodey, G. P.
1993.
What's new in fungal infection in leukemic patients.
Leukem. Lymph.
11(Suppl. 2):S127-S135.
|
| 8.
|
Calderone, R., and J. Sturtevant.
1994.
Macrophage interactions with Candida.
Immunol. Ser.
60:505-515[Medline].
|
| 9.
|
Castro, M.,
J. A. Bjoraker,
M. S. Rohrbach, and A. H. Limper.
1996.
Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes.
Inflammation
20:107-122[CrossRef][Medline].
|
| 10.
|
Chinen, T.,
M. H. Qureshi,
Y. Koguchi, and K. Kawakami.
1999.
Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFN- )- and lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages.
Clin. Exp. Immunol.
115:491-497[CrossRef][Medline].
|
| 11.
|
Coffey, M. J.,
S. M. Phare,
S. Cinti,
M. Peters-Golden, and P. H. Kazanjian.
1999.
Granulocyte-macrophage colony-stimulating factor upregulates reduced 5-lipoxygenase metabolism in peripheral blood monocytes and neutrophils in acquired immunodeficiency syndrome.
Blood
94:3897-3905[Abstract/Free Full Text].
|
| 12.
|
DeGroote, M. A., and F. C. Fang.
1999.
Antimicrobial properties of nitric oxide, p. 231-264.
In
F. C. Fang (ed.), Nitric oxide and infection. Kluwer Academic/Plenum Publishers, New York, N.Y.
|
| 13.
|
Diamond, R. D.,
E. Huber, and C. C. Haudenschild.
1983.
Mechanisms of destruction of Aspergillus fumigatus hyphae mediated by human monocytes.
J. Infect. Dis.
147:474-483[Medline].
|
| 14.
|
Dignani, M. C.,
E. J. Anaissie,
J. P. Hester,
S. O'Brien,
S. E. Vartivarian,
J. H. Rex,
H. Kantarjian,
D. B. Jendiroba,
B. Lichtiger,
B. S. Andersson, and E. J. Freireich.
1997.
Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.
Leukemia
11:1621-1630[CrossRef][Medline].
|
| 15.
|
Fridkin, S. K., and W. R. Jarvis.
1996.
Epidemiology of nosocomial fungal infections.
Clin. Microbiol. Rev.
9:499-511[Abstract].
|
| 16.
|
Futenma, M.,
K. Kawakami, and A. Saito.
1995.
Production of tumor necrosis factor- in granulocytopenic mice with pulmonary candidiasis and its modification with granulocyte colony-stimulating factor.
Microbiol. Immunol.
39:411-417[Medline].
|
| 17.
|
Garcha, U. K.,
E. Brummer, and D. A. Stevens.
1995.
Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species.
J. Infect. Dis.
172:1620-1623[Medline].
|
| 18.
|
Giles, F. J.
1998.
Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants.
Clin. Infect. Dis.
26:1282-1289[Medline].
|
| 19.
|
Ghezzi, M. C.,
G. Raponi,
S. Angeletti, and C. Mancini.
1998.
Serum-mediated enhancement of TNF- release by human monocytes stimulated with the yeast form of Candida albicans.
J. Infect. Dis.
178:1743-1749[CrossRef][Medline].
|
| 20.
|
Gujral, S.,
E. Brummer, and D. A. Stevens.
1996.
Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans.
J. Infect. Dis.
174:888-890[Medline].
|
| 21.
|
Jones, T. C.
1994.
Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF).
Stem Cells
12(Suppl. 1):S229-S240.
|
| 22.
|
Kao, A. S.,
M. E. Brandt,
W. R. Pruitt,
L. A. Conn,
B. A. Perkins,
D. S. Stephens,
W. S. Baughman,
A. L. Reingold,
G. A. Rothrock,
M. A. Pfaller,
R. W. Pinner, and R. A. Hajjeh.
1999.
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.
Clin. Infect. Dis.
29:1164-1170[CrossRef][Medline].
|
| 23.
|
Koshland, D. E.
1992.
The molecule of the year.
Science
258:1861[Free Full Text].
|
| 24.
|
Kullberg, B. J.,
J. W. van't Wout,
R. J. M. Poell, and R. van Furth.
1992.
Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice.
Antimicrob. Agents Chemother.
36:1225-1229[Abstract/Free Full Text].
|
| 25.
|
Levitz, S. M.,
A. Tabuni,
S. Nong, and D. T. Golenbock.
1996.
Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide.
Infect. Immun.
64:945-951[Abstract].
|
| 26.
|
Li, S. P.,
S. Lee, and J. E. Domer.
1998.
Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A.
Infect. Immun.
66:1392-1399[Abstract/Free Full Text].
|
| 27.
|
Louie, A.,
A. L. Baltch,
R. P. Smith,
M. A. Franke,
W. J. Ritz,
J. K. Singh, and M. Gordon.
1995.
Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of disseminated candidiasis.
J. Infect. Dis.
171:406-415[Medline].
|
| 28.
|
Louie, A.,
A. L. Baltch,
R. P. Smith,
M. Franke,
W. Ritz,
J. Singh, and M. A. Gordon.
1994.
Tumor necrosis factor has a protective effect in a murine model of systemic candidiasis.
Infect. Immun.
62:2761-2772[Abstract/Free Full Text].
|
| 29.
|
Moncada, S.,
R. M. J. Palmer, and E. A. Higgs.
1991.
Nitric oxide: physiology, pathophysiology, and pharmacology.
Pharmacol. Rev.
43:109-142[Medline].
|
| 30.
|
Mühl, H., and C. Dinarello.
1999.
Cytokine regulation of nitric oxide production, p. 77-94.
In
F. C. Fang (ed.), Nitric oxide and infection. Kluwer Academic/Plenum Publishers, New York, N.Y.
|
| 31.
|
Natarajan, U.,
N. Randhawa,
E. Brummer, and D. A. Stevens.
1998.
Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophage and synergy with fluconazole.
J. Med. Microbiol.
47:359-363[Abstract/Free Full Text].
|
| 32.
|
Nathan, C. F.
1989.
Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G.
Blood
73:301-306[Abstract/Free Full Text].
|
| 33.
|
National Committee for Clinical Laboratory Standards.
1997.
Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standard M27-T.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 34.
|
Nemunaitis, J.
1997.
A comparative review of colony-stimulating factors.
Drugs
54:709-729[Medline].
|
| 35.
|
Nemunaitis, J.
1998.
Use of macrophage colony-stimulating factor in the treatment of fungal infections.
Clin. Infect. Dis.
26:1279-1281[Medline].
|
| 36.
|
Nemunaitis, J.,
C. D. Buckner,
K. S. Dorsey,
D. Willis,
W. Meyer, and F. Appelbaum.
1998.
Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer.
Am. J. Clin. Oncol.
21:341-346[CrossRef][Medline].
|
| 37.
|
Nemunaitis, J.,
K. Shannon-Dorcy,
F. R. Appelbaum,
J. Meyers,
A. Owens,
R. Day,
D. Ando,
C. O'Neill,
D. Buckner, and J. Singer.
1993.
Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor.
Blood
82:1422-1427[Abstract/Free Full Text].
|
| 38.
|
Opal, S. M.,
J. C. Wherry, and P. Grint.
1998.
Interleukin-10: potential benefits and possible risks in clinical infectious diseases.
Clin. Infect. Dis.
27:1497-1507[Medline].
|
| 39.
|
Pascual, A.,
I. Garcia,
C. Conejo, and E. J. Perea.
1993.
Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes.
Antimicrob. Agents Chemother.
37:187-190[Abstract/Free Full Text].
|
| 40.
|
Peters, B. G.,
D. R. Adkins,
B. R. Harrison,
W. S. Velasquez,
F. R. Dunphy,
P. J. Petruska,
C. E. Bowers,
R. Niemeyer,
W. McIntyre,
D. Vrahnos,
S. E. Auberry, and G. Spitzer.
1996.
Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
Bone Marrow Transplant.
18:93-102[Medline].
|
| 41.
|
Pfaller, M. A.
1996.
Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission.
Clin. Infect. Dis.
22(Suppl.):S89-S94.
|
| 42.
|
Pick, E., and D. Mizel.
1981.
Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader.
J. Immunol. Methods
46:211-226[CrossRef][Medline].
|
| 43.
|
Polonelli, L., and A. Cassone.
1999.
Novel strategies for treating candidiasis.
Curr. Opin. Infect. Dis.
12:61-66.
|
| 44.
|
Poynton, C. H.
1990.
Interferon and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia.
Clin. Infect. Dis.
26:1270-1278.
|
| 45.
|
Rodriguez-Adrian, L. J.,
M. L. Grazziutti,
J. H. Rex, and E. J. Anaissie.
1998.
The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?
Clin. Infect. Dis.
26:1270-1278[Medline].
|
| 46.
|
Roilides, E.,
I. Kadiltsoglou,
A. Dimitriadou,
M. Hatzistilianou,
A. Manitsa,
J. Karpouzas,
P. A. Pizzo, and T. J. Walsh.
1997.
Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia.
FEMS Immunol. Med. Microbiol.
19:169-180[CrossRef][Medline].
|
| 47.
|
Roilides, E.,
A. Anastasio-Katsiardani,
A. Dimitriadou-Georgiadou,
I. Kadiltsoglou,
S. Tsaparidou,
C. Pantelliadis, and T. J. Walsh.
1998.
Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus.
J. Infect. Dis.
178:1734-1742[CrossRef][Medline].
|
| 48.
|
Rowe, J. M.,
J. W. Andersen,
J. J. Mazza,
J. M. Bennett,
E. Paietta,
F. A. Hayes,
D. Oette,
P. A. Cassileth,
E. A. Stadtmauer, and P. H. Wiernik.
1995.
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
Blood
86:457-462[Abstract/Free Full Text].
|
| 49.
|
Rowe, J. M.
1998.
Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections.
Clin. Infect. Dis.
26:1290-1294[Medline].
|
| 50.
|
Schneemann, M.,
G. Schoedon,
S. Hofer,
N. Blau,
L. Guerrero, and A. Schaffner.
1993.
Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes.
J. Infect. Dis.
167:1358-1363[Medline].
|
| 51.
|
Shimokawa, O., and H. Nakayama.
1992.
Increased sensitivity of Candida albicans cells accumulating 14 -methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents.
Antimicrob. Agents Chemother.
36:1626-1629[Abstract/Free Full Text].
|
| 52.
|
Smith, P. D.,
C. L. Lamerson,
S. M. Banks,
S. S. Saini,
L. M. Wahl,
R. A. Calderone, and S. M. Wahl.
1990.
Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans.
J. Infect. Dis.
161:999-1005[Medline].
|
| 53.
|
Stuart, A., and J. K. Ord.
1991.
Kendall's advanced theory of statistics, vol. 2. , p. 1101-1153.
Oxford University Press, New York, N.Y.
|
| 54.
|
Tonnetti, L.,
R. Spaccapelo,
E. Cenci,
A. Mencacci,
P. Puccetti,
R. L. Coffman,
F. Bistoni, and L. Romani.
1995.
Interleukin-4 and -10 exacerbate candidiasis in mice.
Eur. J. Immunol.
25:1559-1565[Medline].
|
| 55.
|
Torosantucci, A.,
P. Chiani,
I. Quinti,
C. M. Ausiello,
I. Mezzaroma, and A. Cassone.
1997.
Responsiveness of human polymorphonuclear cells (PMNL) to stimulation by a mannoprotein fraction (MP-F2) of Candida albicans; enhanced production of IL-6 and tumour necrosis factor-alpha (TNF- ) by MP-F2-stimulated PMNL from HIV-infected subjects.
Clin. Exp. Immunol.
107:451-457[CrossRef][Medline].
|
| 56.
|
Van't Wout, J. W.,
I. Meynaar,
I. Linde,
R. Poell,
H. Mattie, and R. Van Furth.
1990.
Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages.
J. Antimicrob. Chemother.
25:803-811[Abstract/Free Full Text].
|
| 57.
|
Vazquez, N.,
H. R. Buckley, and T. J. Rogers.
1996.
Production of IL-6 and TNF- by the macrophage-like cell line RAW 264.7 after treatment with a cell wall extract of Candida albicans.
J. Interferon Cytokine Res.
16:465-470[Medline].
|
| 58.
|
Vazquez, J. A.,
S. Gupta, and A. Villaneuva.
1998.
Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients.
Eur. J. Clin. Microbiol. Infect. Dis.
17:781-783[CrossRef][Medline].
|
| 59.
|
Vazquez-Torres, A.,
J. Jones-Carson,
T. Warner, and E. Balish.
1995.
Nitric oxide enhances resistance of SCID mice to mucosal candidiasis.
J. Infect. Dis.
172:192-198[Medline].
|
| 60.
|
Vonk, A. G.,
M. G. Netea,
N. E. J. Denecker,
I. C. M. M. Verschueren,
J. W. M. van der Meer, and B. J. Kullberg.
1998.
Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B.
J. Antimicrob. Chemother.
42:469-474[Abstract/Free Full Text].
|
| 61.
|
Walsh, T. J.,
J. W. Hiemenz, and E. Anaissie.
1996.
Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.
Infect. Dis. Clin. N. Am.
10:365-400[CrossRef][Medline].
|
| 62.
|
Wang, Y.,
S. P. Li,
S. A. Moser,
K. L. Bost, and J. E. Domer.
1998.
Cytokine involvement in immunomodulatory activity affected by Candida albicans mannan.
Infect. Immun.
66:1384-1391[Abstract/Free Full Text].
|
| 63.
|
Yamamoto, Y.,
T. W. Klein,
M. Tomioka, and H. Friedman.
1997.
Differential effects of granulocyte/macrophage colony-stimulating factor (GM-CSF) in enhancing macrophage resistance to Legionella pneumophila vs. Candida albicans.
Cell. Immunol.
176:75-81[CrossRef][Medline].
|
Antimicrobial Agents and Chemotherapy, January 2001, p. 96-104, Vol. 45, No. 1
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.1.96-104.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Baltch, A. L., Bopp, L. H., Smith, R. P., Ritz, W. J., Michelsen, P. B.
(2008). Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J Antimicrob Chemother
62: 1285-1290
[Abstract]
[Full Text]
-
Bopp, L. H., Baltch, A. L., Ritz, W. J., Michelsen, P. B., Smith, R. P.
(2006). Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.. J Med Microbiol
55: 865-870
[Abstract]
[Full Text]
-
Patera, A. C., Menzel, F., Jackson, C., Brieland, J. K., Halpern, J., Hare, R., Cacciapuoti, A., Loebenberg, D.
(2004). Effect of Granulocyte Colony-Stimulating Factor Combination Therapy on Efficacy of Posaconazole (SCH56592) in an Inhalation Model of Murine Pulmonary Aspergillosis. Antimicrob. Agents Chemother.
48: 3154-3158
[Abstract]
[Full Text]
-
Marcil, A., Harcus, D., Thomas, D. Y., Whiteway, M.
(2002). Candida albicans Killing by RAW 264.7 Mouse Macrophage Cells: Effects of Candida Genotype, Infection Ratios, and Gamma Interferon Treatment. Infect. Immun.
70: 6319-6329
[Abstract]
[Full Text]
-
Coste, A., Linas, M. D., Cassaing, S., Bernad, J., Chalmeton, S., Seguela, J. P., Pipy, B.
(2002). A sub-inhibitory concentration of amphotericin B enhances candidastatic activity of interferon-{gamma}- and interleukin-13-treated murine peritoneal macrophages. J Antimicrob Chemother
49: 731-740
[Abstract]
[Full Text]